Treanda
(Bendamustine)ApprovedSmall molecule
Bendamustine is used to treat certain types of blood cancers, including chronic lymphocytic leukemia and lymphomas. It works by damaging cancer cell DNA to stop them from growing and multiplying.[2] Treanda is currently approved and in use across 41 indications[4].[1]
Treanda is one of 677 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.
41
Indications
238
Total Trials
50
Active Trials
676
Competitors
8
FDA Applications
NDA/BLA/ANDA regulatory filings
41
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 41 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Treanda
AAzurity Pharmaceuticals
Approved
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Avastin
RochePreclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma47 trials
Show 44 more trials
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Withdrawn·—·Phase 1/2·NCT01170052·20 enrolled
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
Completed·—·Phase 1·NCT02257242·11 enrolled
A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma
Unknown status·IIstituto Nazionale Tumori IRCCS - Fondazione G. Pascale·Phase 1/2·NCT01412307·36 enrolled
Chronic Lymphocytic Leukemia26 trials
Show 23 more trials
Multiple Myeloma17 trials
Show 14 more trials
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Completed·—·Phase 2·NCT01701076·50 enrolled
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Terminated·—·Phase 1/2·NCT02002598·23 enrolled
Mantle Cell Lymphoma14 trials
Show 11 more trials
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Active, not recruiting·—·Phase 2·NCT01661881·23 enrolled
Follicular Lymphoma13 trials
Show 10 more trials
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Completed·—·Phase 2·NCT01234766·39 enrolled
56 more indications
Diffuse Large B-Cell Lymphoma11 trials
Show 8 more trials
Relapsed/Refractory5 trials
Relapsed or Refractory3 trials
Macroglobulinemia3 trials
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07169565·21 enrolled
Breast Cancer3 trials
T-cell non-Hodgkin lymphoma2 trials
Leukemia2 trials
TED2 trials
Acute Leukemia2 trials
CLL2 trials
Stem Cell Transplant2 trials
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma2 trials
Induction Therapy1 trial
Brain Metastases From Solid Tumors1 trial
Function1 trial
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Completed·—·Phase 1·NCT01832922·8 enrolled
Chronic Lymphocytic Leukaemia (CLL)1 trial
Stem Cell Transplantation1 trial
Nivolumab1 trial
ART1 trial
Hematologic Malignancies1 trial
NHL1 trial
AIN1 trial
Ovarian Cancer1 trial
AL amyloidosis1 trial
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Completed·—·Phase 2·NCT01222260·40 enrolled
Radiation Therapy1 trial
Efficacy and Safety1 trial
Advanced Solid Tumors1 trial
Efficacy1 trial
Hairy Cell Leukemia1 trial
Secondary Progressive Multiple Sclerosis1 trial
Prostate Cancer1 trial
Non-Hodgkins Lymphoma1 trial
Carboplatin1 trial
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT01458366·38 enrolled
Brentuximab Vedotin1 trial
Dexamethasone1 trial
Induction Chemotherapy1 trial
TIA1 trial
Regulatory
FDA Approval Timeline[5]
May 1, 2009
TREANDA
NDA NDA022249
Dec 7, 2015
BENDEKA
NDA NDA208194
May 15, 2018
BELRAPZO
NDA NDA205580
Dec 7, 2022
VIVIMUSTA
NDA NDA212209
Dec 7, 2022
BENDAMUSTINE HYDROCHLORIDE
NDA NDA215033
Dec 15, 2022
BENDAMUSTINE HYDROCHLORIDE
NDA NDA216078
Dec 15, 2022
BENDAMUSTINE HYDROCHLORIDE
NDA NDA211530
Jul 3, 2025
BENDAMUSTINE HYDROCHLORIDE
NDA NDA219014
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Treanda drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Bendamustine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAzurity Pharmaceuticals
Patent Landscape[6]
Patent Cliff
Mar 26, 2029
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8895756Jan 12, 2026
8609863Jan 12, 2026
8791270Jan 12, 2026
8609863*PEDJul 12, 2026
8791270*PEDJul 12, 2026
36 more patents
8895756*PEDJul 12, 2026
8669279Mar 26, 2029
8883836Mar 26, 2029
8445524Mar 26, 2029
9533955Mar 26, 2029
8344006Sep 23, 2029
9533955*PEDSep 26, 2029
8445524*PEDSep 26, 2029
8883836*PEDSep 26, 2029
8669279*PEDSep 26, 2029
8344006*PEDMar 23, 2030
8436190Oct 26, 2030
12350257Jan 28, 2031
11103483Jan 28, 2031
11844783Jan 28, 2031
9572797Jan 28, 2031
10010533Jan 28, 2031
12138248Jan 28, 2031
9265831Jan 28, 2031
11872214Jan 28, 2031
9572796Jan 28, 2031
8436190*PEDApr 26, 2031
8609707Aug 11, 2031
9572887Mar 15, 2033
9000021Mar 15, 2033
9597398Mar 15, 2033
9597399Mar 15, 2033
9034908Mar 15, 2033
9597397Mar 15, 2033
9579384Mar 15, 2033
10052385Mar 15, 2033
9144568Mar 15, 2033
11707450Jul 29, 2042
11844784Jul 29, 2042
12419867Jul 29, 2042
12208086Jul 29, 2042